SaO038THE ASSOCIATION OF SERUM CALPROTECTIN (S100A8/A9) LEVELS WITH DISEASE RELAPSE IN PR3-ANCA ASSOCIATED VASCULITIS
Ruth J. Pepper(University College Hospital), Alan D. Salama(The Royal Free Hospital), Juliana Draibe(The Royal Free Hospital), Ulrich Specks(Mayo Clinic), Peter A. Merkel(University of Pennsylvania), John H. Stone(Massachusetts General Hospital)
Cited by 1
Related Papers
A multicenter, randomized, double‐blind, placebo‐controlled trial of adjuvant methotrexate treatment for giant cell arteritis
|Arthritis & Rheumatism|2002|574
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids
|Annals of the Rheumatic Diseases|2013|454
Apremilast for Behçet’s Syndrome — A Phase 2, Placebo-Controlled Study
|New England Journal of Medicine|2015|241
The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases
|The American Journal of Medicine|1996|178
Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids
|Nephrology Dialysis Transplantation|2009|156